美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Palvella Therapeutics

79.60

-0.4900-0.61%

盤後：79.600.00000.00%17:01 EST

成交量：17.56萬

成交額：1,397.32萬

市值：9.42億

市盈率：-22.56

高：80.20

開：79.67

低：78.37

收：80.09

52周最高：114.69

52周最低：17.31

股本：1,183.65萬

流通股本：715.85萬

量比：0.71

換手率：2.45%

股息：- -

股息率：- -

每股收益(TTM):-3.5291

每股收益(LYR):-7.8322

淨資產收益率：-301.19%

總資產收益率：-47.54%

市淨率：24.36

市盈率(LYR):-10.16

資料載入中...

總覽公司新聞資訊公告

Palvella Therapeutics, Inc.盤中異動股價大漲5.03%

Palvella Therapeutics發布公司進展與2026年展望：推進後期臨牀階段管線，以平台化策略攻克無FDA批准療法的嚴重罕見皮膚病及血管畸形

BUZZ-Palvella Therapeutics 在 Truist 上調預期薪酬後攀升

Palvella Therapeutics 獲得 FDA 快速通道認證，用於治療血管角化瘤的 Qtorin™ 3.9% 乾燥雷帕黴素凝膠 (Qtorin™ Rapamycin)

Palvella Therapeutics公布Qtorin™ 3.9%無水雷帕黴素凝膠（Qtorin™ Rapamycin）治療皮膚靜脈畸形的二期Toiva臨牀試驗積極頂線結果

Palvella Therapeutics股價上漲11.2%，因Raymond James將評級從「跑贏大盤」上調至「強烈買入」

Palvella Therapeutics發布2025年第三季度財務業績並提供公司更新

Palvella Therapeutics：Raymond James將評級上調至強力買入，目標價格由92美元提高至143美元

Palvella Therapeutics 宣佈推出 Qtorin™ 新產品候選者 Qtorin™ Pitavastatin，用於治療一種罕見的慢性前癌性遺傳皮膚疾病——擴散性淺表性光敏性角化病（Dsap），該疾病尚無 FDA 批准的治療方案

美國食品藥品監督管理局授予Palvella Therapeutics孤兒產品資助第二年資金，支持Qtorin™雷帕黴素治療微囊性淋巴管畸形的三期Selva試驗

BUZZ-Truist Securities上調Palvella Therapeutics的PT值，看好其先導藥物潛力

Palvella Therapeutics宣佈拓展Qtorin™雷帕黴素的開發範圍，用於治療臨牀意義重大的血管角化瘤——一種罕見的慢性致殘性淋巴疾病，目前尚無FDA批准的療法

Palvella Therapeutics完成Qtorin™雷帕黴素治療皮膚靜脈畸形的2期Toiva試驗患者入組

Palvella Therapeutics任命資深科學家兼生物製藥高管David W. Osborne博士為首席創新官，進一步充實領導團隊

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PVLA/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":79.6,"timestamp":1771448400000,"preClose":80.09,"halted":0,"volume":175593,"hourTrading":{"tag":"盘后","latestPrice":79.6,"preClose":79.6,"latestTime":"17:01 EST","volume":1004,"amount":79903.55,"timestamp":1771452104005,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.006118117118242091,"floatShares":7158500,"shares":11836490,"eps":-3.529122,"marketStatus":"未開盤","change":-0.49,"latestTime":"02-18 16:00:00 EST","open":79.67,"high":80.195,"low":78.37,"amount":13973194.01181,"amplitude":0.022787,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.529122,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771491600000},"marketStatusCode":0,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":80.09,"preHourTrading":{"tag":"盘前","latestPrice":79.8,"preClose":80.09,"latestTime":"09:19 EST","volume":85,"amount":6783,"timestamp":1771424378576,"change":-0.29,"changeRate":-0.003621,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":79.6,"preClose":79.6,"latestTime":"17:01 EST","volume":1004,"amount":79903.55,"timestamp":1771452104005,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.713687,"impliedVol":2.2789,"impliedVolPercentile":0.992},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":7158500,"roa":"-47.54%","roe":"-301.19%","lyrEps":-7.832217,"volumeRatio":0.713687,"shares":11836490,"dividePrice":0,"high":80.195,"amplitude":0.022787,"preClose":80.09,"low":78.37,"week52Low":17.31,"pbRate":"24.36","week52High":114.69,"institutionHeld":0,"latestPrice":79.6,"eps":-3.529122,"divideRate":0,"volume":175593,"delay":0,"ttmEps":-3.529122,"open":79.67,"prevYearClose":104.67,"prevWeekClose":81.54,"prevMonthClose":76.69,"prevQuarterClose":104.67,"fiveDayClose":81.01,"twentyDayClose":98.01,"sixtyDayClose":96.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-11","symbol":"PVLA","fiscalQuarterEnding":"2025/09","expectedEps":-0.85,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762837200000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-08-14","symbol":"PVLA","fiscalQuarterEnding":"2025/06","expectedEps":-0.78,"name":null,"time":"盤前","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.86},{"market":"US","date":"2025-05-15","symbol":"PVLA","fiscalQuarterEnding":"2025/03","expectedEps":-3.4,"name":null,"time":"盤前","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.74},{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"盤前","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":16,"updateTime":1768194000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2026-02-17","current":-22.555185,"percent":0.219931,"low":-39.17838,"twenty":-29.476878,"median":-17.026789,"eighty":20.066674,"high":46.119317,"avg":-10.326411,"sd":23.631822,"marketCap":965147394},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812},{"date":"2025-07-03","current":-11.552339,"twenty":-13.745115,"median":18.829404,"eighty":30.565975,"marketCap":266662639},{"date":"2025-07-11","current":-12.902986,"twenty":-13.143371,"median":-9.82332,"eighty":30.216104,"marketCap":297839615},{"date":"2025-07-18","current":-14.957693,"twenty":-13.611836,"median":-10.196903,"eighty":29.977556,"marketCap":345268417},{"date":"2025-07-25","current":-18.501942,"twenty":-13.979479,"median":-10.548775,"eighty":29.89804,"marketCap":427080338},{"date":"2025-08-01","current":-17.520089,"twenty":-14.593892,"median":-10.570486,"eighty":26.844623,"marketCap":404416225},{"date":"2025-08-08","current":-18.703103,"twenty":-14.909501,"median":-10.577479,"eighty":25.683689,"marketCap":431723718},{"date":"2025-08-15","current":-17.957373,"twenty":-15.155991,"median":-10.795594,"eighty":24.999851,"marketCap":509666156},{"date":"2025-08-22","current":-19.99406,"twenty":-15.421442,"median":-10.987175,"eighty":24.729496,"marketCap":567471411},{"date":"2025-08-29","current":-19.990163,"twenty":-15.528887,"median":-11.165181,"eighty":23.854819,"marketCap":567360814},{"date":"2025-09-05","current":-21.096831,"twenty":-16.235493,"median":-11.305678,"eighty":23.549477,"marketCap":598770263},{"date":"2025-09-12","current":-22.776317,"twenty":-17.271569,"median":-11.413443,"eighty":23.46678,"marketCap":646437419},{"date":"2025-09-19","current":-23.006223,"twenty":-17.715742,"median":-11.554734,"eighty":23.433384,"marketCap":652962621},{"date":"2025-09-26","current":-22.480166,"twenty":-18.057474,"median":-11.868448,"eighty":22.814749,"marketCap":638032073},{"date":"2025-10-03","current":-24.405145,"twenty":-18.52589,"median":-11.961844,"eighty":22.305846,"marketCap":692666818},{"date":"2025-10-10","current":-27.312096,"twenty":-18.938434,"median":-12.127082,"eighty":22.115008,"marketCap":775171919},{"date":"2025-10-17","current":-28.500595,"twenty":-19.602341,"median":-12.457671,"eighty":21.593382,"marketCap":808903898},{"date":"2025-10-24","current":-27.783599,"twenty":-20.103168,"median":-12.65393,"eighty":21.227608,"marketCap":788554114},{"date":"2025-10-31","current":-30.558062,"twenty":-20.870432,"median":-12.719639,"eighty":21.154454,"marketCap":867298929},{"date":"2025-11-07","current":-30.639894,"twenty":-21.250362,"median":-12.96286,"eighty":21.08766,"marketCap":869621458},{"date":"2025-11-14","current":-28.915921,"twenty":-22.006325,"median":-13.231068,"eighty":21.033589,"marketCap":952837445},{"date":"2025-11-21","current":-32.881534,"twenty":-22.215189,"median":-13.745115,"eighty":20.998602,"marketCap":1083512294},{"date":"2025-11-28","current":-36.922579,"twenty":-22.816843,"median":-13.778174,"eighty":20.973157,"marketCap":1216672807},{"date":"2025-12-05","current":-33.693335,"twenty":-23.242364,"median":-14.278382,"eighty":20.931809,"marketCap":1110262762},{"date":"2025-12-12","current":-34.763763,"twenty":-24.512694,"median":-14.593892,"eighty":20.769596,"marketCap":1145535502},{"date":"2025-12-19","current":-34.569792,"twenty":-27.267674,"median":-14.831115,"eighty":20.674177,"marketCap":1139143797},{"date":"2025-12-26","current":-38.014559,"twenty":-27.693195,"median":-14.933597,"eighty":20.674177,"marketCap":1252655736},{"date":"2026-01-02","current":-37.597882,"twenty":-28.489684,"median":-15.118842,"eighty":20.670996,"marketCap":1238925408},{"date":"2026-01-09","current":-34.979285,"twenty":-28.647112,"median":-15.258978,"eighty":20.655092,"marketCap":1152637396},{"date":"2026-01-16","current":-37.350031,"twenty":-29.232399,"median":-15.408801,"eighty":20.639189,"marketCap":1230758230},{"date":"2026-01-23","current":-33.075504,"twenty":-29.325414,"median":-15.443563,"eighty":20.626467,"marketCap":1089903999},{"date":"2026-01-30","current":-29.418807,"twenty":-29.517639,"median":-15.528887,"eighty":20.515145,"marketCap":969408531},{"date":"2026-02-06","current":-27.453961,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"marketCap":904662930},{"date":"2026-02-13","current":-29.461912,"twenty":-29.48062,"median":-17.007828,"eighty":20.117564,"marketCap":970828909},{"date":"2026-02-17","current":-29.289494,"twenty":-29.476878,"median":-17.026789,"eighty":20.066674,"marketCap":965147394}],"updateTime":1771484084707},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606894223","title":"Palvella Therapeutics, Inc.盤中異動 股價大漲5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606894223","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606894223?lang=zh_tw&edition=fundamental","pubTime":"2026-01-26 23:07","pubTimestamp":1769440063,"startTime":"0","endTime":"0","summary":"北京时间2026年01月26日23时07分，Palvella Therapeutics, Inc.股票出现异动，股价大幅拉升5.03%。Palvella Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.54%。其相关个股中，Seastar Medical Holding Corp C/Wts 28/10/2027 、Acumen Pharmaceuticals, Inc.、Cel-Sci Corporation涨幅较大，Revelation Biosciences, Inc.、60 Degrees Pharmaceuticals, Inc.、Dermata Therapeutics, Inc.较为活跃，换手率分别为54.65%、40.57%、29.96%，振幅较大的相关个股有Acumen Pharmaceuticals, Inc.、Dermata Therapeutics, Inc.、Novabay Pharmaceuticals, Inc.，振幅分别为41.91%、32.26%、29.75%。Palvella Therapeutics, Inc.公司简介：Palvella Therapeutics Inc 是一家晚期临床阶段的生物制药公司，致力于为那些患有严重的、罕见的遗传皮肤病的患者提供治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126230743953e6b2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126230743953e6b2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","PVLA","LENZ","BK4007"],"gpt_icon":0},{"id":"1134522020","title":"Palvella Therapeutics發布公司進展與2026年展望：推進後期臨牀階段管線，以平台化策略攻克無FDA批准療法的嚴重罕見皮膚病及血管畸形","url":"https://stock-news.laohu8.com/highlight/detail?id=1134522020","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134522020?lang=zh_tw&edition=fundamental","pubTime":"2026-01-09 20:30","pubTimestamp":1767961814,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics近期披露了公司最新动态及面向2026年的战略规划。该公司正全力推进其处于后期临床阶段的产品管线与技术平台，致力于解决目前尚无美国食品药品监督管理局（FDA）批准疗法的多种严重罕见皮肤病及血管畸形疾病。这一举措凸显了公司聚焦未满足临床需求的战略方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2592931275","title":"BUZZ-Palvella Therapeutics 在 Truist 上調預期薪酬後攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2592931275","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592931275?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 02:38","pubTimestamp":1765910315,"startTime":"0","endTime":"0","summary":"BUZZ-Palvella Therapeutics 在 Truist 上调预期薪酬后攀升12月16日 - ** 药物开发商Palvella Therapeutics PVLA.O股价上涨6.14%至94.45美元** Truist将目标股价从105美元上调至190美元，较上一交易日上涨113.5%。** Truist称，该公司Qtorin凝胶的小型概念验证研究为皮肤静脉畸形患者提供了充分的 \"去风险 \"机会，皮肤静脉畸形是一种导致静脉功能障碍的罕见遗传性皮肤病。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nL4S3XM15O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1132581978","title":"Palvella Therapeutics 獲得 FDA 快速通道認證，用於治療血管角化瘤的 Qtorin™ 3.9% 乾燥雷帕黴素凝膠 (Qtorin™ Rapamycin)","url":"https://stock-news.laohu8.com/highlight/detail?id=1132581978","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132581978?lang=zh_tw&edition=fundamental","pubTime":"2025-12-16 20:30","pubTimestamp":1765888255,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics 获得 FDA 快速通道认证，用于治疗血管角化瘤的 Qtorin™ 3.9% 干燥雷帕霉素凝胶 (Qtorin™ Rapamycin)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1123205248","title":"Palvella Therapeutics公布Qtorin™ 3.9%無水雷帕黴素凝膠（Qtorin™ Rapamycin）治療皮膚靜脈畸形的二期Toiva臨牀試驗積極頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1123205248","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123205248?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 19:01","pubTimestamp":1765796473,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics公布Qtorin™ 3.9%无水雷帕霉素凝胶（Qtorin™ Rapamycin）治疗皮肤静脉畸形的二期Toiva临床试验积极顶线结果。这是一种严重的罕见遗传疾病，目前尚无FDA批准的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1134453895","title":"Palvella Therapeutics股價上漲11.2%，因Raymond James將評級從「跑贏大盤」上調至「強烈買入」","url":"https://stock-news.laohu8.com/highlight/detail?id=1134453895","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134453895?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 01:28","pubTimestamp":1763573311,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics股价上涨11.2%，因Raymond James将评级从“跑赢大盘”上调至“强烈买入”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1121184983","title":"Palvella Therapeutics發布2025年第三季度財務業績並提供公司更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1121184983","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121184983?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 01:24","pubTimestamp":1763573099,"startTime":"0","endTime":"0","summary":"11月11日 - Palvella Therapeutics Inc 发表声明：*PALVELLA THERAPEUTICS发布2025年第三季度财务业绩并提供公司更新*PALVELLA THERAPEUTICS INC：第三季度每股收益为-$1.03","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"1156492120","title":"Palvella Therapeutics：Raymond James將評級上調至強力買入，目標價格由92美元提高至143美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156492120","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156492120?lang=zh_tw&edition=fundamental","pubTime":"2025-11-19 20:12","pubTimestamp":1763554332,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics：Raymond James将评级上调至强力买入，目标价格由92美元提高至143美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"1160931524","title":"Palvella Therapeutics 宣佈推出 Qtorin™ 新產品候選者 Qtorin™ Pitavastatin，用於治療一種罕見的慢性前癌性遺傳皮膚疾病——擴散性淺表性光敏性角化病（Dsap），該疾病尚無 FDA 批准的治療方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1160931524","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160931524?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 19:01","pubTimestamp":1762340484,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics 宣布推出 Qtorin™ 新产品候选者 Qtorin™ Pitavastatin，用于治疗一种罕见的慢性前癌性遗传皮肤疾病——扩散性浅表性光敏性角化病（Dsap），该疾病尚无 FDA 批准的治疗方案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"1189215679","title":"美國食品藥品監督管理局授予Palvella Therapeutics孤兒產品資助第二年資金，支持Qtorin™雷帕黴素治療微囊性淋巴管畸形的三期Selva試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1189215679","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189215679?lang=zh_tw&edition=fundamental","pubTime":"2025-10-13 19:30","pubTimestamp":1760355015,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局授予Palvella Therapeutics孤儿产品资助第二年资金，用于支持该公司Qtorin™雷帕霉素治疗微囊性淋巴管畸形的三期Selva临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2572546101","title":"BUZZ-Truist Securities上調Palvella Therapeutics的PT值，看好其先導藥物潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=2572546101","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572546101?lang=zh_tw&edition=fundamental","pubTime":"2025-10-02 23:51","pubTimestamp":1759420267,"startTime":"0","endTime":"0","summary":"BUZZ-Truist Securities上调Palvella Therapeutics的PT值，看好其先导药物潜力10月2日 - ** Truist Securities将药物开发商Palvella Therapeutics PVLA.O的预测价格从56美元上调至80美元。** 券商认为Palvella的主要候选药物QTORIN雷帕霉素很有潜力，该药物正在治疗微囊性淋巴畸形的后期试验中。** 如果试验成功，新适应症取得进展，Truist 将看到该药物的商业机会** PT的提升也反映了PVLA围绕潜在资本提升的计划。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nL3T3VJ0Z1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1177709996","title":"Palvella Therapeutics宣佈拓展Qtorin™雷帕黴素的開發範圍，用於治療臨牀意義重大的血管角化瘤——一種罕見的慢性致殘性淋巴疾病，目前尚無FDA批准的療法","url":"https://stock-news.laohu8.com/highlight/detail?id=1177709996","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177709996?lang=zh_tw&edition=fundamental","pubTime":"2025-09-24 18:02","pubTimestamp":1758708121,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布拓展Qtorin™雷帕霉素的开发范围，用于治疗临床意义重大的血管角化瘤——一种罕见的慢性致残性淋巴疾病，目前尚无FDA批准的疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"1107503642","title":"Palvella Therapeutics完成Qtorin™雷帕黴素治療皮膚靜脈畸形的2期Toiva試驗患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=1107503642","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107503642?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 19:30","pubTimestamp":1757935818,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics已完成其Qtorin™雷帕霉素用于治疗皮肤静脉畸形的2期Toiva临床试验的患者招募工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1102713602","title":"Palvella Therapeutics任命資深科學家兼生物製藥高管David W. Osborne博士為首席創新官，進一步充實領導團隊","url":"https://stock-news.laohu8.com/highlight/detail?id=1102713602","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102713602?lang=zh_tw&edition=fundamental","pubTime":"2025-09-03 19:30","pubTimestamp":1756899025,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布任命经验丰富的科学家兼生物制药行业高管David W. Osborne博士担任首席创新官，以此举措进一步加强公司领导层实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA","ARQT"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}